Generalized Anxiety Disorder (GAD) is a common mental health condition characterized by excessive and uncontrollable worry. It affects many individuals, disrupting their daily lives, social interactions, and work activities.
Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. It affects the nose, throat, and sometimes the lungs, leading to mild to severe illness and even death. Recognizing flu symptoms early on is crucial for effective treatment and prevention. Early detection allows for timely medical intervention and helps prevent spreading the virus to others.
Welcome to Part 2 of our exploration into anxiety. Last year, we discussed common behaviors and symptoms associated with Social Anxiety Disorder in our blog: If You Can Relate, You May Have Social Anxiety Disorder. Today, we delve deeper, offering new insights and the latest information to help you understand this pervasive condition. If you find yourself relating to these experiences, it may be time to consider professional avenues, including potential participation in a clinical trial for anxiety.
Miami Lakes, FL – Segal Trials, a leading clinical research organization specializing in acute schizophrenia trials, has been recognized by the PPD Select Global Partnership Program for outstanding enrollment performance. This accolade was awarded for the site’s exemplary participation in the Phase 2 study of CVL-231 (Emraclidine), aimed at treating patients experiencing an acute exacerbation of psychosis.
[North Miami, FL – [August 21, 2024] – Segal Trials is proud to announce the completion of the first injection procedure in the DigniFI Study. The Women’s Health Team, under the leadership of Principal Investigator Steven Chavoustie, M.D., FACOG and Sub-Investigator Brittany Berre MSN, ARNP, FNP-C, worked diligently to prepare for this vital women's health study. The study's first injection procedure was performed on August 19, 2024.. Segal Trials also completed the first muscle tissue procurement procedure for the study on March 21, 2024.
The FDA's recent decision to pause the approval of MDMA-assisted therapy for PTSD is a reminder of the complexities in advancing groundbreaking treatments. While the...
In the field of medical research, the study of women's health is essential, illuminating unique health needs and leading the way in personalized medicine. Historically, much of medical research has focused on male subjects, leaving gaps in our understanding of female-specific health issues. As we advance in healthcare, the focused study of women’s health and sex differences not only improves our understanding but also drives innovations that promise better health outcomes for everyone. This article explores the significant impact of female-centric clinical studies and highlights the efforts of institutions like Segal Trials to address these critical areas.
Learn the untold story of Adult ADHD—go beyond distraction. Explore what defines this complex condition, uncover the unique challenges and surprising strengths, and learn about the effective treatments that can help manage symptoms and enhance daily life. Hoping this comprehensive guide will help embrace the vibrant possibilities of living with ADHD.
In the evolving landscape of medical research, the inclusion of diverse populations in clinical trials is critical. Each individual's unique genetic background and lifestyle factors significantly influence both the efficacy and safety of new medications. Historically, the lack of diversity in clinical trials has been a glaring issue, with significant repercussions. It has not only failed to address the needs of all populations but has also stifled innovation, costing the pharmaceutical industry billions, as highlighted in recent studies.
The team at Segal Trials’ Center for Psychedelic Research closely followed the recent session of the FDA’s Psychopharmacologic Drugs Advisory Committee. This pivotal meeting focused on the New Drug Application (NDA) submitted by Lykos Therapeutics for MDMA-assisted therapy for Post-Traumatic Stress Disorder (PTSD). Despite compelling presentations and data showing significant efficacy and a low incidence of serious adverse events, the committee voted against FDA approval. This vote, however, is non-binding, and the FDA’s final decision is expected by August 11, 2024.